Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans

Tomoko Yamazaki, Mayumi Mori, Satoko Arai, Ryosuke Tateishi, Masanori Abe, Mihoko Ban, Akemi Nishijima, Maki Maeda, Takeharu Asano, Toshihiro Kai, Kiyohiro Izumino, Jun Takahashi, Kayo Aoyama, Sei Harada, Toru Takebayashi, Toshiaki Gunji, Shin Ohnishi, Shinji Seto, Yukio Yoshida, Yoichi HiasaKazuhiko Koike, Ken Ichi Yamamura, Ken Ichiro Inoue, Toru Miyazaki

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC. Methods and Findings: Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99±1.8 μg/ml in men and 6.06±2.1 μg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis. Conclusion: AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.

Original languageEnglish
Article numbere109123
JournalPLoS One
Volume9
Issue number10
DOIs
Publication statusPublished - 2014 Oct 10

Fingerprint

Macrophages
hepatoma
Liver
Hepatocellular Carcinoma
macrophages
apoptosis
Apoptosis
liver
carbon tetrachloride
Carbon Tetrachloride
Fibrosis
Blood
Inhibitor of Apoptosis Proteins
neoplasms
liver function
fatty liver
blood
mice
Wounds and Injuries
liver diseases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Yamazaki, T., Mori, M., Arai, S., Tateishi, R., Abe, M., Ban, M., ... Miyazaki, T. (2014). Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. PLoS One, 9(10), [e109123]. https://doi.org/10.1371/journal.pone.0109123

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. / Yamazaki, Tomoko; Mori, Mayumi; Arai, Satoko; Tateishi, Ryosuke; Abe, Masanori; Ban, Mihoko; Nishijima, Akemi; Maeda, Maki; Asano, Takeharu; Kai, Toshihiro; Izumino, Kiyohiro; Takahashi, Jun; Aoyama, Kayo; Harada, Sei; Takebayashi, Toru; Gunji, Toshiaki; Ohnishi, Shin; Seto, Shinji; Yoshida, Yukio; Hiasa, Yoichi; Koike, Kazuhiko; Yamamura, Ken Ichi; Inoue, Ken Ichiro; Miyazaki, Toru.

In: PLoS One, Vol. 9, No. 10, e109123, 10.10.2014.

Research output: Contribution to journalArticle

Yamazaki, T, Mori, M, Arai, S, Tateishi, R, Abe, M, Ban, M, Nishijima, A, Maeda, M, Asano, T, Kai, T, Izumino, K, Takahashi, J, Aoyama, K, Harada, S, Takebayashi, T, Gunji, T, Ohnishi, S, Seto, S, Yoshida, Y, Hiasa, Y, Koike, K, Yamamura, KI, Inoue, KI & Miyazaki, T 2014, 'Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans', PLoS One, vol. 9, no. 10, e109123. https://doi.org/10.1371/journal.pone.0109123
Yamazaki T, Mori M, Arai S, Tateishi R, Abe M, Ban M et al. Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. PLoS One. 2014 Oct 10;9(10). e109123. https://doi.org/10.1371/journal.pone.0109123
Yamazaki, Tomoko ; Mori, Mayumi ; Arai, Satoko ; Tateishi, Ryosuke ; Abe, Masanori ; Ban, Mihoko ; Nishijima, Akemi ; Maeda, Maki ; Asano, Takeharu ; Kai, Toshihiro ; Izumino, Kiyohiro ; Takahashi, Jun ; Aoyama, Kayo ; Harada, Sei ; Takebayashi, Toru ; Gunji, Toshiaki ; Ohnishi, Shin ; Seto, Shinji ; Yoshida, Yukio ; Hiasa, Yoichi ; Koike, Kazuhiko ; Yamamura, Ken Ichi ; Inoue, Ken Ichiro ; Miyazaki, Toru. / Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. In: PLoS One. 2014 ; Vol. 9, No. 10.
@article{7314161224024c079e1f292375ece7d8,
title = "Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans",
abstract = "Background: Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC. Methods and Findings: Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99±1.8 μg/ml in men and 6.06±2.1 μg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis. Conclusion: AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.",
author = "Tomoko Yamazaki and Mayumi Mori and Satoko Arai and Ryosuke Tateishi and Masanori Abe and Mihoko Ban and Akemi Nishijima and Maki Maeda and Takeharu Asano and Toshihiro Kai and Kiyohiro Izumino and Jun Takahashi and Kayo Aoyama and Sei Harada and Toru Takebayashi and Toshiaki Gunji and Shin Ohnishi and Shinji Seto and Yukio Yoshida and Yoichi Hiasa and Kazuhiko Koike and Yamamura, {Ken Ichi} and Inoue, {Ken Ichiro} and Toru Miyazaki",
year = "2014",
month = "10",
day = "10",
doi = "10.1371/journal.pone.0109123",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans

AU - Yamazaki, Tomoko

AU - Mori, Mayumi

AU - Arai, Satoko

AU - Tateishi, Ryosuke

AU - Abe, Masanori

AU - Ban, Mihoko

AU - Nishijima, Akemi

AU - Maeda, Maki

AU - Asano, Takeharu

AU - Kai, Toshihiro

AU - Izumino, Kiyohiro

AU - Takahashi, Jun

AU - Aoyama, Kayo

AU - Harada, Sei

AU - Takebayashi, Toru

AU - Gunji, Toshiaki

AU - Ohnishi, Shin

AU - Seto, Shinji

AU - Yoshida, Yukio

AU - Hiasa, Yoichi

AU - Koike, Kazuhiko

AU - Yamamura, Ken Ichi

AU - Inoue, Ken Ichiro

AU - Miyazaki, Toru

PY - 2014/10/10

Y1 - 2014/10/10

N2 - Background: Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC. Methods and Findings: Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99±1.8 μg/ml in men and 6.06±2.1 μg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis. Conclusion: AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.

AB - Background: Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC. Methods and Findings: Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99±1.8 μg/ml in men and 6.06±2.1 μg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis. Conclusion: AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.

UR - http://www.scopus.com/inward/record.url?scp=84907853293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907853293&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0109123

DO - 10.1371/journal.pone.0109123

M3 - Article

C2 - 25302503

AN - SCOPUS:84907853293

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e109123

ER -